[TITLE]U.S. Healthcare System Seriously Threatened by Private Equity Takeover:
[TEXT]
The health of many Americans is seriously under threat because private equity firms are taking over hospitals. These private equity firms have taken over some 450 hospitals across the United States.

Private equity firm Steward had acquired over 37 hospitals in the United States alone.

Besides hospitals, reports state that the takeover has extended into the acquisitions of 750 nursing homes, 200 emergency set-ups, 5,779 doctor’s practices and two-thirds of the country’s air ambulances.

In this growing takeover trend, over the last 10 years, these private equity investors have paid out around $1 trillion in the last 10 years.

Succinctly put by Massachusetts State Senator Cindy Friedman:

“Private equity is the complete opposite of the delivery of healthcare…” She goes on to say “… make money, leave, make it however you want, make it for people who are interested in making money, and then you have got healthcare, which is all
[Source link]: https://www.activistpost.com/u-s-healthcare-system-seriously-threatened-by-private-equity-takeover/


[TITLE]Amazon invests over $1 billion to raise employee pay, lower healthcare costs:
[TEXT]
Amazon.com said on Wednesday it is investing more than $1 billion to raise pay and lower healthcare costs for U.S. fulfillment and transportation employees, pushing up the average total compensation to over $30 an hour including benefits.

The technology giant said the average pay would increase to more than $23 per hour, adding that full-time employees will see their pay increase by $1,600 per year, on average.

The company is lowering the cost of its entry-level health care plan to $5 per week and $5 for co-pays, starting in 2026, representing a 34 per cent drop in weekly contributions from employees.

Amazon had more than 1.5 million full-time and part-time employees at the end of last year. The company also hires temporary workers and independent contractors seasonally, particularly around the crucial holiday season.

Subscribe to our Chief Editor’s Week in Review Our chief editor shares analysis and picks of the week's biggest news every Saturday. This service is not intended for persons residing in the E.U. By clicking subscribe, I agree to receive news updates and promotional material from Mediacorp and Mediacorp’s partners. Loading Loading

Last year, Amazon workers at seven U.S. facilities had walked off the job during the holiday shopping rush, after union officials said the retailer had failed to come to the bargaining table to negotiate contracts. Employees were protesting what they said was Amazon's unfair treatment of its workers.

In December, Amazon also agreed to implement safety measures at all of its U.S. facilities to settle a federal agency's claims that it failed to prevent workers from developing back problems and other ergonomic injuries.
[Source link]: https://www.channelnewsasia.com/business/amazon-invests-over-1-billion-raise-employee-pay-lower-healthcare-costs-5354306


[TITLE]Inspire Investing LLC Has $344,000 Stake in Sabra Healthcare REIT, Inc. $SBRA:
[TEXT]
Inspire Investing LLC decreased its holdings in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA – Free Report) by 15.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,683 shares of the real estate investment trust’s stock after selling 3,469 shares during the quarter. Inspire Investing LLC’s holdings in Sabra Healthcare REIT were worth $344,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC bought a new position in Sabra Healthcare REIT in the 1st quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/17/inspire-investing-llc-has-344000-stake-in-sabra-healthcare-reit-inc-sbra/


[TITLE]Voya Investment Management LLC Grows Position in Alignment Healthcare, Inc. $ALHC:
[TEXT]
Voya Investment Management LLC increased its holdings in Alignment Healthcare, Inc. (NASDAQ:ALHC – Free Report) by 408.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,293,414 shares of the company’s stock after acquiring an additional 1,038,940 shares during the quarter. Voya Investment Management LLC owned approximately 0.65% of Alignment Healthcare worth $24,083,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ALHC. Northern Trust Corp lifted its position in shares of Alignment Healthcare by 8.6% during the fourth quarter. Northern Trust Corp now owns 908,964 shares of the company’s stock valued at $10,226,000 after buying an additional 72,063 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Alignment Healthcare during the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/15/voya-investment-management-llc-grows-position-in-alignment-healthcare-inc-alhc/

================================================================================

[TITLE]U.S. Healthcare System Seriously Threatened by Private Equity Takeover:
[TEXT]
The health of many Americans is seriously under threat because private equity firms are taking over hospitals. These private equity firms have taken over some 450 hospitals across the United States.

Private equity firm Steward had acquired over 37 hospitals in the United States alone.

Besides hospitals, reports state that the takeover has extended into the acquisitions of 750 nursing homes, 200 emergency set-ups, 5,779 doctor’s practices and two-thirds of the country’s air ambulances.

In this growing takeover trend, over the last 10 years, these private equity investors have paid out around $1 trillion in the last 10 years.

Succinctly put by Massachusetts State Senator Cindy Friedman:

“Private equity is the complete opposite of the delivery of healthcare…” She goes on to say “… make money, leave, make it however you want, make it for people who are interested in making money, and then you have got healthcare, which is all
[Source link]: https://www.activistpost.com/u-s-healthcare-system-seriously-threatened-by-private-equity-takeover/


[TITLE]Amazon invests over $1 billion to raise employee pay, lower healthcare costs:
[TEXT]
Amazon.com said on Wednesday it is investing more than $1 billion to raise pay and lower healthcare costs for U.S. fulfillment and transportation employees, pushing up the average total compensation to over $30 an hour including benefits.

The technology giant said the average pay would increase to more than $23 per hour, adding that full-time employees will see their pay increase by $1,600 per year, on average.

The company is lowering the cost of its entry-level health care plan to $5 per week and $5 for co-pays, starting in 2026, representing a 34 per cent drop in weekly contributions from employees.

Amazon had more than 1.5 million full-time and part-time employees at the end of last year. The company also hires temporary workers and independent contractors seasonally, particularly around the crucial holiday season.

Subscribe to our Chief Editor’s Week in Review Our chief editor shares analysis and picks of the week's biggest news every Saturday. This service is not intended for persons residing in the E.U. By clicking subscribe, I agree to receive news updates and promotional material from Mediacorp and Mediacorp’s partners. Loading Loading

Last year, Amazon workers at seven U.S. facilities had walked off the job during the holiday shopping rush, after union officials said the retailer had failed to come to the bargaining table to negotiate contracts. Employees were protesting what they said was Amazon's unfair treatment of its workers.

In December, Amazon also agreed to implement safety measures at all of its U.S. facilities to settle a federal agency's claims that it failed to prevent workers from developing back problems and other ergonomic injuries.
[Source link]: https://www.channelnewsasia.com/business/amazon-invests-over-1-billion-raise-employee-pay-lower-healthcare-costs-5354306


[TITLE]Financiere des Professionnels Fonds d investissement inc. Invests $208,000 in HCA Healthcare, Inc. $HCA:
[TEXT]
Financiere des Professionnels Fonds d investissement inc. acquired a new position in HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 542 shares of the company’s stock, valued at approximately $208,000.

Several other large investors also recently made changes to their positions in HCA. Brighton Jones LLC acquired a new stake in shares of HCA Healthcare in the 4th quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/19/financiere-des-professionnels-fonds-d-investissement-inc-invests-208000-in-hca-healthcare-inc-hca/


[TITLE]Inspire Investing LLC Has $344,000 Stake in Sabra Healthcare REIT, Inc. $SBRA:
[TEXT]
Inspire Investing LLC decreased its holdings in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA – Free Report) by 15.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,683 shares of the real estate investment trust’s stock after selling 3,469 shares during the quarter. Inspire Investing LLC’s holdings in Sabra Healthcare REIT were worth $344,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC bought a new position in Sabra Healthcare REIT in the 1st quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/17/inspire-investing-llc-has-344000-stake-in-sabra-healthcare-reit-inc-sbra/

================================================================================

[TITLE]SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics:
[TEXT]
West Conshohocken, PA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc. (“Y-mAbs”), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer.

“We are excited to welcome Y-mAbs into SERB. The acquisition strengthens our Rare Oncology portfolio with the addition of Danyelza® (naxitamab-gqgk) and brings deep oncology expertise that will help us to expand our partnerships with the US oncology community and to advance treatments for rare and hard-to-treat cancers”, said Vanessa Wolfeler, Chief Executive Officer of SERB. “This marks a significant step forward in delivering on SERB’s growth strategy and vision, but more importantly, it allows us to help more children and families facing pediatric cancers.”

Completion of Tender Offer and Transaction Details

The tender offer period, initiated on August 18, 2025, expired at one minute following 11:59 p.m., Eastern Time, on September 15, 2025. The conditions of the tender offer having been satisfied, SERB has accepted all such tendered shares for $8.60 per share, and following a statutory merger under Section 251(h) of the Delaware General Corporation Law on September 16, 2025, Y-mAbs became a wholly owned subsidiary of SERB and was delisted from the Nasdaq Global Select Market. All remaining Y-mAbs shares that were not tendered in the tender offer will be converted into the right to receive the same $8.60 per share in cash paid for shares that were tendered in the tender offer.
[Source link]: https://www.globenewswire.com/news-release/2025/09/16/3150821/0/en/SERB-Pharmaceuticals-Completes-Acquisition-of-Y-mAbs-Therapeutics.html


[TITLE]Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals CVKD:
[TEXT]
Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4197935/CVKD-Cadrenal-announces-acquisition-of-assets-of-eXIthera-Pharmaceuticals


[TITLE]UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 2,774,933 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR:
[TEXT]
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 138.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,785,062 shares of the biotechnology company’s stock after purchasing an additional 2,774,933 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC’s holdings in Arrowhead Pharmaceuticals were worth $60,962,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ARWR. GAMMA Investing LLC increased its stake in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $49,000. CWM LLC grew its stake in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,523 shares during the last quarter. KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the first quarter worth $133,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Get Arrowhead Pharmaceuticals alerts:

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ARWR shares. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Royal Bank Of Canada dropped their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Finally, B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $43.14.

Insider Activity

In other news, insider James C. Hamilton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 25,000 shares of company stock worth $575,000. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $29.72 on Monday. The firm’s 50-day moving average price is $19.99 and its 200-day moving average price is $16.52. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $31.13. The firm has a market capitalization of $4.11 billion, a P/E ratio of -23.22 and a beta of 1.00. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter last year, the firm posted ($1.38) earnings per share. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Articles

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/15/ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-acquires-2774933-shares-of-arrowhead-pharmaceuticals-inc-arwr/


[TITLE]Intech Investment Management LLC Increases Holdings in Crinetics Pharmaceuticals, Inc. $CRNX:
[TEXT]
Intech Investment Management LLC raised its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 32.1% during the first quarter, Holdings Channel.com reports. The firm owned 56,950 shares of the company’s stock after purchasing an additional 13,845 shares during the period. Intech Investment Management LLC’s holdings in Crinetics Pharmaceuticals were worth $1,910,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Exome Asset Management LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the 1st quarter valued at $1,720,000. Amalgamated Bank grew its stake in Crinetics Pharmaceuticals by 17.3% during the 1st quarter. Amalgamated Bank now owns 3,159 shares of the company’s stock worth $106,000 after purchasing an additional 467 shares in the last quarter. GAMMA Investing LLC grew its stake in Crinetics Pharmaceuticals by 6,291.5% during the 1st quarter. GAMMA Investing LLC now owns 6,775 shares of the company’s stock worth $227,000 after purchasing an additional 6,669 shares in the last quarter. Swiss National Bank grew its stake in Crinetics Pharmaceuticals by 1.5% during the 1st quarter. Swiss National Bank now owns 161,800 shares of the company’s stock worth $5,427,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Crinetics Pharmaceuticals by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 9,311,600 shares of the company’s stock worth $312,311,000 after purchasing an additional 222,209 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Get Crinetics Pharmaceuticals alerts:

Analyst Ratings Changes

Several research firms recently commented on CRNX. HC Wainwright reissued a “buy” rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Friday, June 27th. The Goldman Sachs Group began coverage on Crinetics Pharmaceuticals in a research note on Thursday, July 10th. They set a “neutral” rating and a $36.00 target price for the company. Finally, JMP Securities lowered their target price on Crinetics Pharmaceuticals from $90.00 to $86.00 and set a “market outperform” rating for the company in a research note on Monday, August 11th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $65.33.

Crinetics Pharmaceuticals Stock Performance

Crinetics Pharmaceuticals stock opened at $34.10 on Wednesday. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $24.10 and a fifty-two week high of $62.53. The company has a market capitalization of $3.21 billion, a P/E ratio of -8.30 and a beta of 0.28. The stock has a 50-day simple moving average of $31.12 and a 200-day simple moving average of $31.35.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.10). The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.52 million. The business’s revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.94) earnings per share. As a group, analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current year.

Insider Activity

In other news, insider Dana Pizzuti sold 30,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $30.43, for a total transaction of $912,900.00. Following the completion of the transaction, the insider directly owned 66,270 shares of the company’s stock, valued at approximately $2,016,596.10. This represents a 31.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.
[Source link]: https://www.etfdailynews.com/2025/09/17/intech-investment-management-llc-increases-holdings-in-crinetics-pharmaceuticals-inc-crnx/

================================================================================

[TITLE]Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum:
[TEXT]
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
[Source link]: https://www.globenewswire.com/news-release/2025/09/19/3153401/0/en/Royalty-Pharma-to-Present-at-Bernstein-s-2nd-Annual-Healthcare-Forum.html


[TITLE]Fetal Bovine Serum Market Size to Hit USD 6.03 Billion by 2033 Due to Increasing Demand for Cell-based Research and Biopharmaceutical Production | S&S Insider:
[TEXT]
Austin, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Fetal Bovine Serum
[Source link]: https://www.globenewswire.com/news-release/2025/09/19/3153161/0/en/Fetal-Bovine-Serum-Market-Size-to-Hit-USD-6-03-Billion-by-2033-Due-to-Increasing-Demand-for-Cell-based-Research-and-Biopharmaceutical-Production-S-S-Insider.html


[TITLE]Biobanking Market Analysis and Forecast Report 2025-2035: Ethical and Legal Challenges in Biobanking - Navigating Consent and Privacy:
[TEXT]
Dublin, Sept. 19, 2025 (GLOBE NEWSWIRE) -- The "Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup.

Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.

The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.

Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.

Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.

Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.

The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.

The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.

Biobanking Market Outlook

One of the most significant emerging trends in the global biobanking market is the integration of digital technologies and automation. This trend involves the adoption of advanced data management systems, AI-driven platforms, and automation in sample collection, storage, and analysis. These technologies improve the efficiency, accuracy, and scalability of biobanking operations, making it easier to manage large volumes of biological samples. Automation helps streamline processes, reduces human error, and enhances the reliability of sample handling, which is crucial for maintaining sample integrity.

Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks.

With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.

Key Topics Covered:

1. Global Biobanking Market: Industry Outlook

1.1 Introduction

1.2 Market Trends

1.3 Regulatory Framework

1.4 Case Studies

1.5 Product Benchmarking

1.6 Market Dynamics

2. Global Biobanking Market (by Product and Service)

2.1 Equipment

2.2 Consumables

2.3 Services

2.4 Software

3. Global Biobanking Market (by Storage Type)

3.1 Manual Storage

3.2 Automated Storage

4. Global Biobanking Market (by Sample Type)

4.1 Blood Products

4.2 Human Tissues

4.3 Cell Lines

4.4 Nucleic Acids

4.5 Biological Fluids

4.6 Human Waste Products

5. Global Biobanking Market (by Ownership)

5.1 Universities

5.2 National/Regional Agencies

5.3 Non-Profit Organizations

5.4 Private Organizations

6. Global Biobanking Market (by Biobank Type)

6.1 Physical/Real Biobanks

6.2 Tissue Biobanks

6.3 Population-Based Biobanks

6.4 Genetic (DNA/RNA)

6.5 Disease-Based Biobanks

6.6 Virtual Biobanks

7. Global Biobanking Market (by Application)

7.1 Regenerative Medicine

7.2 Life Science Research

7.3 Clinical Research

8. Global Biobanking Market (by End User)

8.1 Pharmaceutical & Biotechnology Companies and Cros

8.2 Academic And Research Institutes

8.3 Hospitals

9. Global Biobanking Market (by Region)

10. Global Biobanking Market: Competitive Landscape and Company Profiles

10.1 Key Strategies and Development

10.2 Company Profiles

Becton, Dickinson and Company

QIAGEN N.V.

Merck KGaA

Thermo Fisher Scientific Inc.

PHC Holdings Corporation

Cryoport, Inc.

Azenta, Inc.

Avantor, Inc.

Tecan Trading AG

Greiner AG

Bay Biosciences LLC

Shanghai Zhangjiang Biobank

US Biolab Corporation, Inc.

Cureline

Brooks Life Sciences
[Source link]: https://www.globenewswire.com/news-release/2025/09/19/3153011/28124/en/Biobanking-Market-Analysis-and-Forecast-Report-2025-2035-Ethical-and-Legal-Challenges-in-Biobanking-Navigating-Consent-and-Privacy.html


[TITLE]Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups:
[TEXT]
WALTHAM, Mass., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today announced that Endpoints News has named Sironax to its Endpoints 11 list of the most promising private biotech companies of 2025. The annual recognition honors biotech startups for their discipline, strategic focus, and potential to grow in today’s business environment. Sironax was honored at an awards gala in Boston on Sept. 18, 2025.

“We are thrilled to have received this distinguished recognition from Endpoint News as a reflection of our scientific innovation to date,” said Dr. Shefali Agarwal, President and CEO of Sironax. “Our extensive research capabilities have enabled us to develop a robust clinical pipeline with potential application across numerous conditions. To advance our clinical programs, we recently expanded our global presence into additional key markets, highlighted by our new administrative headquarters in the U.S. Supported by our Board of Directors, leading investors, and a dedicated global team of approximately 160 employees, we believe we are well positioned to continue our growth and bring patients novel treatments for degenerative diseases affecting longevity, diseases requiring supportive care, and certain immunology and inflammation diseases.”

Sironax’s pipeline targets key contributors of aging and degeneration: dysregulated cellular death, uncontrolled inflammation, and disrupted energy homeostasis. This pipeline consists of proprietary SARM1 inhibition, NAMPT activation, and RIPK1 inhibition clinical-stage programs with potentially first-in-class or best-in-class assets, and several undisclosed preclinical programs. In addition, under its strategic agreement with Novartis , Sironax granted the pharmaceutical company an exclusive option to acquire its proprietary Brain Delivery Module platform, while retaining certain development rights.

To advance its clinical programs and global growth strategy, Sironax recently established its administrative headquarters in Waltham, Massachusetts and European operations in Basel, Switzerland. In addition to comprehensive research centers in Beijing and Shanghai, China, the company maintains a presence in Sydney, Australia. Since its founding in 2017, Sironax has raised over $300 million, including a $200 million Series B financing in 2022.
[Source link]: https://www.globenewswire.com/news-release/2025/09/19/3153269/0/en/Sironax-Named-to-2025-Endpoints-11-List-of-the-Most-Promising-Biotech-Startups.html

================================================================================

[TITLE]U.S. Healthcare System Seriously Threatened by Private Equity Takeover:
[TEXT]
The health of many Americans is seriously under threat because private equity firms are taking over hospitals. These private equity firms have taken over some 450 hospitals across the United States.

Private equity firm Steward had acquired over 37 hospitals in the United States alone.

Besides hospitals, reports state that the takeover has extended into the acquisitions of 750 nursing homes, 200 emergency set-ups, 5,779 doctor’s practices and two-thirds of the country’s air ambulances.

In this growing takeover trend, over the last 10 years, these private equity investors have paid out around $1 trillion in the last 10 years.

Succinctly put by Massachusetts State Senator Cindy Friedman:

“Private equity is the complete opposite of the delivery of healthcare…” She goes on to say “… make money, leave, make it however you want, make it for people who are interested in making money, and then you have got healthcare, which is all
[Source link]: https://www.activistpost.com/u-s-healthcare-system-seriously-threatened-by-private-equity-takeover/


[TITLE]Amazon invests over $1 billion to raise employee pay, lower healthcare costs:
[TEXT]
Amazon.com said on Wednesday it is investing more than $1 billion to raise pay and lower healthcare costs for U.S. fulfillment and transportation employees, pushing up the average total compensation to over $30 an hour including benefits.

The technology giant said the average pay would increase to more than $23 per hour, adding that full-time employees will see their pay increase by $1,600 per year, on average.

The company is lowering the cost of its entry-level health care plan to $5 per week and $5 for co-pays, starting in 2026, representing a 34 per cent drop in weekly contributions from employees.

Amazon had more than 1.5 million full-time and part-time employees at the end of last year. The company also hires temporary workers and independent contractors seasonally, particularly around the crucial holiday season.

Subscribe to our Chief Editor’s Week in Review Our chief editor shares analysis and picks of the week's biggest news every Saturday. This service is not intended for persons residing in the E.U. By clicking subscribe, I agree to receive news updates and promotional material from Mediacorp and Mediacorp’s partners. Loading Loading

Last year, Amazon workers at seven U.S. facilities had walked off the job during the holiday shopping rush, after union officials said the retailer had failed to come to the bargaining table to negotiate contracts. Employees were protesting what they said was Amazon's unfair treatment of its workers.

In December, Amazon also agreed to implement safety measures at all of its U.S. facilities to settle a federal agency's claims that it failed to prevent workers from developing back problems and other ergonomic injuries.
[Source link]: https://www.channelnewsasia.com/business/amazon-invests-over-1-billion-raise-employee-pay-lower-healthcare-costs-5354306


[TITLE]Financiere des Professionnels Fonds d investissement inc. Invests $208,000 in HCA Healthcare, Inc. $HCA:
[TEXT]
Financiere des Professionnels Fonds d investissement inc. acquired a new position in HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 542 shares of the company’s stock, valued at approximately $208,000.

Several other large investors also recently made changes to their positions in HCA. Brighton Jones LLC acquired a new stake in shares of HCA Healthcare in the 4th quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/19/financiere-des-professionnels-fonds-d-investissement-inc-invests-208000-in-hca-healthcare-inc-hca/


[TITLE]Voya Investment Management LLC Grows Position in Alignment Healthcare, Inc. $ALHC:
[TEXT]
Voya Investment Management LLC increased its holdings in Alignment Healthcare, Inc. (NASDAQ:ALHC – Free Report) by 408.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,293,414 shares of the company’s stock after acquiring an additional 1,038,940 shares during the quarter. Voya Investment Management LLC owned approximately 0.65% of Alignment Healthcare worth $24,083,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ALHC. Northern Trust Corp lifted its position in shares of Alignment Healthcare by 8.6% during the fourth quarter. Northern Trust Corp now owns 908,964 shares of the company’s stock valued at $10,226,000 after buying an additional 72,063 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Alignment Healthcare during the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/09/15/voya-investment-management-llc-grows-position-in-alignment-healthcare-inc-alhc/

================================================================================

